^
Association details:
| Biomarker: | RAD50 deletion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RAD50 Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors
Published date:
04/18/2023
Excerpt:
Cell cycle analysis demonstrated an increase in the G2/M population in cells treated with niraparib or rucaparib alone or in combination with carboplatin. T47D-RAD50 deficient cells treated with rucaparib and carboplatin exhibited twofold levels in late apoptosis...T47D RAD50 deficient cells treated with PARP inhibitors alone or in combination with carboplatin showed cell cycle arrest in the G2/M phase, leading to death by apoptosis. Thus, RAD50 deficiency may be a good biomarker for predicting PARPi response.
Secondary therapy:
carboplatin
DOI:
10.2174/1568009623666230418101511
